Tolerability of NXY-059 at higher concentrations in patients with acute stroke "SA-NYX-0004"

Completed

Phase N/A Results

Summary of Purpose

To study the tolerability, safety and plasma concentrations in patients receiving NXY-059.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 3 September 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • AstraZeneca

Trial Design

Randomized, multicenter, double-blind, placebo controlled, dose-escalation trial.

Contacts

  • University Department of Medicine and Therapeutics Western Infirmary Glascow, G11 6NT, UK

    k.r.lees@gla.ac.uk